From DCAT Value Chain Insights (VCI)
MannKind Corporation, a biopharmaceutical company, has announced that Hakan Edstrom has stepped down as the president, chief executive officer (CEO) and as a director of MannKind. The board of directors of MannKind appointed Alfred Mann as interim CEO, effective November 19, 2015. Mr. Mann will continue to serve as the executive chairman of the company. A committee of the board has begun a search for a successor CEO.
MannKind is partnered with Sanofi for Afrezza, a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. It was approved by the US Food and Drug Administration in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of Afrezza. Sanofi is responsible for global commercial, regulatory and development activities and MannKind manufactures Afrezz at its manufacturing facility in Danbury, Connnecticut. For the first nine months of 2015, sales of Afrezza were $17.1 million.
Source: MannKind Corporation
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription